GlassScriptPhysician profile
Michael J Mcnulty
NPI 1013177450
$13,473.70
in general payments reported to CMS, 2019-2025
50 companies · $2,367 in 2025
The $2,367 reported for 2025 was more than what 82% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $1,267 · 2021: $1,351 · 2022: $2,408 · 2023: $2,139 · 2024: $2,596 · 2025: $2,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,102.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,998.83 | 2021-2025 | |
| Boston Scientific Corporation | $2,238.96 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, General - Therapies |
| Abbott Laboratories | $2,135.06 | 2019-2025 | Proclaim, Eterna |
| Lilly USA, LLC | $497.45 | 2019-2024 | Emgality, Reyvow |
| Allergan, INC. | $494.54 | 2019-2022 | |
| Pfizer INC. | $492.59 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $486.01 | 2019-2025 | Ajovy |
| Nevro Corp. | $452.85 | 2019-2024 | Senza |
| Lundbeck LLC | $337.33 | 2022-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $310.69 | 2022 | |
| Averitas Pharma INC. | $309.25 | 2023-2025 | Qutenza |
| Medtronic USA, INC. | $282.55 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $198.61 | 2020-2025 | Dysport |
| Merz North America, INC. | $191.81 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $177.58 | 2020-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcnulty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.